PrenticeRL.Surrogate endpoints in clinical trials: definition and operational criteria.Stat Med1989;
8: 431–440.
2.
BuyseMMolenberghsGBurzykowskiT, et al.
The validation of surrogate endpoints in meta-analyses of randomized experiments.Biostatistics2000;
1: 49–67.
3.
CooperKTappendenPCantrellA, et al.
A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer.Br J Cancer2020;
123: 1686–1696.
4.
ChenEYHaslamAPrasadV.FDA acceptance of surrogate end points for cancer drug approval: 1992-2019.JAMA Intern Med2020;
180: 912–914.
5.
Di MaioMAudisioMCardoneC, et al.
The use of not-negative conclusions to describe results of formally negative trials presented at oncology meetings.JAMA Oncol2020;
6: 926–927.
